Key HighlightsOn July 24, the FDA granted approval for Lytenava (bevacizumab-vikg) to treat wet AMD, arriving two days before the scheduled July 29 decision date.This marks the first FDA-approved ophthalmic bevacizumab product specifically formulated for wet AMD treatment in the United States.Shares of OTLK increased approximately 8.9% during Monday’s pre-market session, following a 6% gain on Friday that closed at $1.41.BTIG initiated coverage with a Buy rating and established a $4.00 price objective for the stock.Wall Street’s average 12-month price forecast stands at $5.50, suggesting potential upside of approximately 290% from present price levels.Shares of Outlook Therapeutics experienced significant gains during Monday’s pre-market hours following the FDA’s approval of Lytenava for treating wet age-related macular degeneration — a crucial regulatory achievement the biotech firm had pursued through several submission cycles.Outlook Therapeutics, Inc., OTLKThe stock advanced approximately 8.9% before the opening bell after recording a 6% increase on Friday, finishing at $1.41 per share. The regulatory green light came on July 24, arriving two business days earlier than the official July 29 PDUFA deadline.With this approval, Lytenava (bevacizumab-vikg) becomes America’s first FDA-sanctioned ophthalmic bevacizumab formulation created exclusively for wet AMD patients.The approval journey presented significant challenges. The FDA issued a Complete Response Letter in December 2025, demanding additional clinical data. Following Outlook’s formal appeal, the agency’s Office of New Drugs determined in May that the company’s existing evidence package was adequate — eliminating the need for further clinical studies.This favorable determination enabled Outlook to file a resubmission in June, ultimately culminating in Friday’s regulatory victory.Wall Street responded swiftly to the news. BTIG elevated OTLK from Neutral to Buy status and assigned a $4.00 price objective, highlighting the approximately $8.5 billion U.S. anti-VEGF retina therapeutics market as a substantial commercial opportunity.Wall Street Price Projections Show Wide VarianceAnalyst sentiment remains divided on the stock. According to Koyfin data, four analysts currently cover OTLK, with two assigning Buy recommendations and two maintaining Hold ratings. The consensus 12-month price forecast of $5.50 suggests approximately 290% potential appreciation from current trading levels.The most bullish projection of $10 per share would translate to 609% upside potential, whereas the most conservative estimate of $0.50 indicates a possible 65% decline.While bevacizumab has been utilized in retinal medicine for more than two decades, its use has predominantly been off-label. According to Outlook’s estimates, millions of ophthalmic injections are delivered each year across the United States.The company anticipates making Lytenava accessible to qualified U.S. patients before the conclusion of 2026. Outlook is currently establishing a dedicated retina-focused sales infrastructure while broadening reimbursement pathways and patient assistance programs.International Commercialization Already in ProgressLytenava has secured regulatory approval throughout the European Union and United Kingdom, with active commercial distribution in Germany, Austria, and the United Kingdom. The company anticipates receiving 12 years of U.S. market exclusivity protection under federal biologics regulations.Outlook recently achieved compliance with Nasdaq’s minimum bid price standard after trading above $1.00 for ten straight sessions — eliminating a potential delisting threat that had weighed on investor sentiment throughout the year.Favorable market conditions also supported the move. The S&P 500 advanced roughly 1.0%, the Dow Jones gained around 1.0%, and the Nasdaq climbed approximately 1.6% on Monday, creating positive momentum for small-capitalization biotechnology stocks.BTIG’s $4.00 price objective and Buy recommendation, published after the FDA approval announcement, represents the most recent formal Wall Street action on the security.The post Outlook Therapeutics (OTLK) Stock Soars 12% Following Lytenava FDA Approval appeared first on Blockonomi.